tlooto
Sign up
Medicine

The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD.

M. Cazzola, M. Molimard

2010.8.1PULMONARY PHARMACOLOGY & THERAPEUTICS

DOI: 10.1016/j.pupt.2010.03.003

tlooto Summary

The scientific rationale for combining LABAs and LAMAs in COPD, the clinical evidence to support these agents given in combination, and their potential role in the management of patients with COPD are illustrated.

Abstract

Abstract is not available.

Citation format

CAZZOLA, M.; MOLIMARD, M. The scientific rationale for combining long-acting beta2-agonists and muscarinic antagonists in COPD. PULMONARY PHARMACOLOGY & THERAPEUTICS, 2010, 23 4: 257–67.